| UniProt ID | 1A02_HUMAN | |
|---|---|---|
| UniProt AC | P01892 | |
| Protein Name | HLA class I histocompatibility antigen, A-2 alpha chain | |
| Gene Name | HLA-A | |
| Organism | Homo sapiens (Human). | |
| Sequence Length | 365 | |
| Subcellular Localization |
Membrane Single-pass type I membrane protein. | |
| Protein Description | Involved in the presentation of foreign antigens to the immune system.. | |
| Protein Sequence | MAVMAPRTLVLLLSGALALTQTWAGSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWEPSSQPTIPIVGIIAGLVLFGAVITGAVVAAVMWRRKSSDRKGGSYSQAASSDSAQGSDVSLTACKV | |
| Overview of Protein Modification Sites with Functional and Structural Information | ||
|
| ||
* ASA = Accessible Surface Area
| Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
|---|---|---|---|---|---|
| 110 | N-linked (GlcNAc) | GTLRGYYNQSEAGSH HHHCCCCCCCCCCCC | 30.34 | 19159218 | |
| 135 | N6-methyllysine | GSDWRFLRGYHQYAY CCCCHHHCCCEEEEE | 40.69 | 115478757 | |
| 145 | Ubiquitinlysine | HQYAYDGKDYIALKE EEEEECCCCEEEEHH | 44.45 | 21906983 21890473 | |
| 151 | Ubiquitinlysine | GKDYIALKEDLRSWT CCCEEEEHHHHHHCH | 39.91 | 21906983 21890473 | |
| 155 | N6-methyllysine | IALKEDLRSWTAADM EEEHHHHHHCHHHHH | 42.33 | 115478751 | |
| 168 | Ubiquitinlysine | DMAAQTTKHKWEAAH HHHHHHCHHHHHHHH | 46.72 | 21906983 21890473 | |
| 188 | S-glutathionyl cysteine | RAYLEGTCVEWLRRY HHHHHCHHHHHHHHH | 3.72 | 22555962 | |
| 200 | Ubiquitinlysine | RRYLENGKETLQRTD HHHHHCCHHHHHCCC | 60.14 | 21906983 21890473 | |
| 267 | N6-methyllysine | AGDGTFQKWAAVVVP CCCCCEEEEEEEEEC | 34.31 | 24623505 | |
| 267 | Ubiquitinlysine | AGDGTFQKWAAVVVP CCCCCEEEEEEEEEC | 34.31 | 21906983 21890473 | |
| 292 | Ubiquitinlysine | VQHEGLPKPLTLRWE EEECCCCCCEEEECC | 58.67 | 21906983 21890473 | |
| 340 | Ubiquitinlysine | RRKSSDRKGGSYSQA HCCCCCCCCCCCCCC | 73.03 | 21906983 21890473 | |
| 344 | Phosphotyrosine | SDRKGGSYSQAASSD CCCCCCCCCCCCCCC | 14.21 | 1956339 | |
| 350 | Phosphoserine | SYSQAASSDSAQGSD CCCCCCCCCCCCCCC | 30.75 | 24275569 | |
| 352 | Phosphoserine | SQAASSDSAQGSDVS CCCCCCCCCCCCCCE | 25.17 | 24275569 | |
| 356 | Phosphoserine | SSDSAQGSDVSLTAC CCCCCCCCCCEEEEE | 23.82 | 18088087 23186163 24275569 | |
| 359 | Phosphoserine | SAQGSDVSLTACKV- CCCCCCCEEEEECC- | 25.62 | 23186163 24275569 | |
| 364 | Ubiquitinlysine | DVSLTACKV------ CCEEEEECC------ | 48.81 | 21906983 21890473 |
* Distance = the distance between SAP position and PTM sites.
| Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
|---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of 1A02_HUMAN !! | ||||||
| Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
|---|---|---|---|---|
| UGGG1_HUMAN | UGGT1 | physical | 17353931 | |
| CD8A_HUMAN | CD8A | physical | 9177355 | |
| CD8A_HUMAN | CD8A | physical | 10809759 | |
| COPB_HUMAN | COPB1 | physical | 11884415 | |
| COPG1_HUMAN | COPG1 | physical | 11884415 | |
| TPSN_HUMAN | TAPBP | physical | 11884415 | |
| TAP1_HUMAN | TAP1 | physical | 11884415 | |
| SYVN1_HUMAN | SYVN1 | physical | 21245296 | |
| UB2J1_HUMAN | UBE2J1 | physical | 21245296 | |
| DERL1_HUMAN | DERL1 | physical | 21245296 | |
| PSMD2_HUMAN | PSMD2 | physical | 21245296 | |
| MAGA4_HUMAN | MAGEA4 | physical | 21815906 | |
| BAP31_HUMAN | BCAP31 | physical | 17056546 | |
| B2MG_HUMAN | B2M | physical | 8805302 | |
| STAT3_HUMAN | STAT3 | physical | 21988832 | |
| GNAS3_HUMAN | GNAS | physical | 9914489 | |
| GNAS2_HUMAN | GNAS | physical | 9914489 | |
| ALEX_HUMAN | GNAS | physical | 9914489 | |
| GNAS1_HUMAN | GNAS | physical | 9914489 | |
| BAG6_HUMAN | BAG6 | physical | 21636303 | |
| MEOX2_HUMAN | MEOX2 | physical | 24722188 |
| Kegg Disease | ||||||
|---|---|---|---|---|---|---|
| OMIM Disease | ||||||
| There are no disease associations of PTM sites. | ||||||
| Kegg Drug | ||||||
| DrugBank | ||||||
| There are no disease associations of PTM sites. | ||||||
| N-linked Glycosylation | |
| Reference | PubMed |
| "Glycoproteomics analysis of human liver tissue by combination ofmultiple enzyme digestion and hydrazide chemistry."; Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.; J. Proteome Res. 8:651-661(2009). Cited for: GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-110, AND MASSSPECTROMETRY. | |
| Phosphorylation | |
| Reference | PubMed |
| "Phosphoproteome of resting human platelets."; Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,Schuetz C., Walter U., Gambaryan S., Sickmann A.; J. Proteome Res. 7:526-534(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352 AND SER-356, ANDMASS SPECTROMETRY. | |
| "Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-352 AND SER-356, ANDMASS SPECTROMETRY. | |